Novo Nordisk has launched its Wegovy weight-loss pill in the US at significantly lower prices than injections.
The once-daily pill is the first GLP-1 tablet approved, offering a needle-free alternative for obesity treatment.
Cash-paying patients can access starting doses for $149 a month, far below typical injectable prices.
Analysts at UBS said pricing was lower than expected, accelerating competition.
The launch challenges rivals including Eli Lilly, which also plans an obesity pill.
Wegovy pills are available at major US pharmacies and telehealth platforms, with wider rollout expected soon.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
